Strides’ arm in pact with Aus­tralia’s SUDA Pharma for mi­graine drug

The Hindu Business Line - - NEWS -

Strides Pharma Sci­ence on Fri­day said its step-down sub­sidiary has en­tered into an ex­clu­sive prod­uct devel­op­ment, li­cens­ing and sup­ply agree­ment with Aus­tralia’s SUDA Phar­ma­ceu­ti­cals for its novel drug SUD-001H, used in the treat­ment of mi­graine.

Strides Pharma Sci­ence said this part­ner­ship is part of its spe­cial­ity port­fo­lio for the US mar­ket. “Un­der the terms of agree­ment, SUDA will re­ceive an up­front cash pay­ment of $0.4 mil­lion and a fur­ther pay­ment of $0.6 mil­lion on reach­ing cer­tain mile­stones in­clud­ing the pi­lot first-in-man clin­i­cal study, sub­mis­sion and ap­proval of the prod­uct in the US,” Strides Pharma Sci­ence said in a BSE fil­ing.

On com­mer­cial sales, SUDA will also re­ceive roy­al­ties plus a han­dling fee. SUD-001H is an oral spray of suma­trip­tan to treat mi­graine headache.

Strides Pharma Sci­ence said the prod­uct will be filed with the US Food and Drug Ad­min­is­tra­tion and on ap­proval is ex­pected to be the first fast-act­ing oral spray of suma­trip­tan in the US mar­ket. The com­pany will have a right of first re­fusal for ad­di­tional ter­ri­to­ries in­clud­ing the EU, Aus­tralia and New Zea­land, Canada, South Africa and Ja­pan.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.